Cabir YÜKSEL, Gökhan ÇELİK, Gözde KÖYCÜ, Aydın ÇİLEDAĞ, Eren GÜRSOY

Oral antikoagülan tedavinin nadir bir komplikasyonu: Hemotoraks

Oral antikoagülan tedavinin en önemli komplikasyonu kanama olmasına rağmen hemotoraks gelişimi oldukça nadirdir. Bu yazıda, plevrada lokalize plakları bulunan, warfarin kullanımına bağlı spontan hemotoraks gelişen ve medikal tedavi ile düzelen bir olgu sık karşılaşılmaması nedeniyle sunulmaktadır. Oral antikoagülan tedavi alan hastaların, etkin antikoagülan tedavinin sağlanabilmesi ve yan etkiler bakımından takip edilmeleri ve bu hastalarda plevral sıvı gelişmesi halinde hemotoraksın ayırıcı tanıda akılda tutulması gerekir. Plevral plaklar ya da kalınlaşma gibi plevral patolojilerin varlığı hemotoraks gelişimi için risk faktörü olabilir.

A rare complication of oral anticoagulant treatment: hemothorax

Although bleeding is the most serious complication of oral anticoagulant treatment, hemothorax is extremely rare. Herein, a case with localized pleural plaques and spontaneous hemothorax due to warfarin treatment which was improved with medical treatment is presented because of its rarity. The patients recieving oral anticoagulant treatment should be monitorized for effective anticoagulation and adverse effects, if pleural effusion occurs, hemothorax should be kept in mind in the differential diagnosis. Pleural pathologies such as pleural plaques or thickening may be risk factors for hemothorax.

PDF

___

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians.Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133 (6 Suppl): S160-S98.
2. Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Emergency department visits foroutpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med 2005; 45: 197-206.
3. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-66.
4. Levine MN, Raskob G, Landefeld CS, Kearon C. Hemorrhagic complications of anticoagulant treatment Chest 2001; 119 (Suppl): 108-21.
5. Markis M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol 2001; 114: 271-80.
6. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non surgical patients. J Thromb Haemost 2005; 3: 692-4.
7. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114 (5 Suppl): S511-S23.
8. Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2000; 172: 600-5.
9. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
10. Landefeld CS, Beyth RJ. Anticoagulant-releated bleeding; clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-28.
11. Nasilowski J, Krenke R. Hemothorax with high number of eosinophils following warfarin overdose. Pneumonol Alergol Pol 2002; 70: 496-503.
12. Moskovitz B, Braner B, Engel A, Kleinhaus U, Levin DR. Multifocal bleeding due to anticoagulant therapy. Urol Int 1988; 43: 53-5.
13. Simon HB, Dagget MW, DeSanctis RW. Hemothorax as a complication of anticoagulant therapy in the presence of pulmonary infarction. JAMA 1969; 208: 1830-4.
14. Akay H. The diagnostic and therapeutic approach in hemothorax. Solunum 2002; 4: 195-205.
15. Ece T. Hemothorax. In: Gözü O, Köktürk O (eds). Pleural Diseases. Thorax Books, Istanbul: Turgut Publishing Company, 2003: 295-302.
16. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): S204-S33.